Patent intelligence · IT
IT MI20070164
CEROTTO TRANSDERMICO
CEROTTO TRANSDERMICO
Patent details — IT MI20070164
- Jurisdiction
- IT
- Status
- granted
- Grant date
- Nov 6, 2007
- Expiration
- Nov 1, 2027
- Applicant
- AXXONIS PHARMA AG
- CPC classes
- A61P/1700
Quick answer
IT MI20070164 (CEROTTO TRANSDERMICO) is held by AXXONIS PHARMA AG. Status: granted. Granted Nov 6, 2007. Expires Nov 1, 2027 (1 year remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- AXXONIS PHARMA AG
- Grant date
- Expiration
- Claims
- —
- CPC classes
- A61P/1700
More from AXXONIS PHARMA AG
Related pharmaceutical patents in our USPTO index.
-
CA 2626142
SOLUTIONS AQUEUSES STABILISEES DE COMPOSES D'ERGOLINE
granted -
DE 102006048130
Transdermales therapeutisches System mit zweiphasigem Freisetzungsprofil
granted -
DE 102004006048
Pharmazeutische Kombination aus Gadolinium Komplexen und kolloidalen Biopolymeren und deren Verwendung als kontrastverstärkendes Mittel zur i.v. Injektion bzw. i.v. Infusion in der MR Angiographie
expired -
DE 10341317
Mittel zur transdermalen Applikation
expired -
AU 2002363847
1-ALLYL ERGOT ALKALOID DERIVATIVES, METHOD FOR PRODUCING THE SAME AND THE USE THEREOF FOR PREVENTING AND TREATING MIGRAINE
expired -
EP 1311248
TRANSDERMALES THERAPEUTISCHES SYSTEM ZUR BEHANDLUNG DES RESTLESS-LEGS-SYNDROMS
expired -
EP 1303278
KOMBINATION EINES TRANSDERMALEN THERAPEUTISCHEN SYSTEMS UND EINER ORALEN UND/ODER PARENTERALEN ZUBEREITUNG ENTHALTEND DOPAMINAGONISTEN ZUR BEHANDLUNG DOPAMINERGER ERKRANKUNGEN
expired
Frequently asked questions
What is US patent MI20070164?
IT MI20070164 (CEROTTO TRANSDERMICO) is held by AXXONIS PHARMA AG. Status: granted. Granted Nov 6, 2007. Expires Nov 1, 2027 (1 year remaining) — relevant for patent-cliff and LOE planning.
Who owns IT MI20070164?
AXXONIS PHARMA AG is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 8 pharmaceutical patents for this assignee.
When does IT MI20070164 expire?
Our index shows an expiration date of Nov 1, 2027 (1 year from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.